NCKAP1L: A Potential Drug Target and Biomarker (G3071)

Target Name: NCKAP1L

NCBI ID: G3071

NCKAP1L

NCKAP1L: A Potential Drug Target and Biomarker

Nckap1l (N-cadherin-associated protein 1-like), also known as NCKAP1L, is a protein that is expressed in various tissues and cell types in the human body. It is a member of the cadherin family, which is a transmembrane protein that plays a crucial role in cell-cell adhesion. NCKAP1L is known for its ability to regulate the actinin cytoskeleton, which is responsible for the maintenance of cell shape and integrity.

The research on NCKAP1L has primarily focused on its role in cancer progression and metastasis. Studies have shown that high levels of NCKAP1L are associated with the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. Additionally, NCKAP1L has been shown to promote the growth and survival of cancer cells in cell culture and animal models.

Despite these promising findings, the precise function of NCKAP1L remains unclear. Some researchers have suggested that it may be a drug target, with potential therapeutic interventions targeting NCKAP1L being investigated in clinical trials. Additionally, NCKAP1L has also been identified as a potential biomarker for cancer diagnosis and monitoring.

One potential mechanism by which NCKAP1L may be a drug target is its role in cell signaling pathways. Studies have shown that NCKAP1L can interact with various signaling molecules, including TGF-β, NF-kappa-B, and PI3K. These interactions may regulate the actinin cytoskeleton and influence the mechanical properties of cells, potentially contributing to the regulation of cell function.

Additionally, NCKAP1L has been shown to play a role in the regulation of cell adhesion and migration. Studies have shown that NCKAP1L can interact with cell adhesion molecules, such as E-cadherin, and influence the distribution of adhesion molecules along the cell membrane. This may contribute to the regulation of cell-cell adhesion and the maintenance of cell integrity.

In conclusion, NCKAP1L is a protein that has been shown to play a critical role in the regulation of cell function and cell-cell adhesion. Its potential as a drug target and biomarker makes it an attractive target for further research and development of therapeutic interventions. Further studies are needed to fully understand the precise function of NCKAP1L and its potential as a therapeutic intervention.

Protein Name: NCK Associated Protein 1 Like

Functions: Essential hematopoietic-specific regulator of the actin cytoskeleton (Probable). Controls lymphocyte development, activation, proliferation and homeostasis, erythrocyte membrane stability, as well as phagocytosis and migration by neutrophils and macrophages (PubMed:16417406, PubMed:17696648). Component of the WAVE2 complex which signals downstream of RAC to stimulate F-actin polymerization. Required for stabilization and/or translation of the WAVE2 complex proteins in hematopoietic cells (By similarity). Within the WAVE2 complex, enables the cortical actin network to restrain excessive degranulation and granule release by T-cells (PubMed:32647003). Required for efficient T-lymphocyte and neutrophil migration (PubMed:32647003). Exhibits complex cycles of activation and inhibition to generate waves of propagating the assembly with actin (PubMed:16417406). Also involved in mechanisms WAVE-independent to regulate myosin and actin polymerization during neutrophil chemotaxis (PubMed:17696648). In T-cells, required for proper mechanistic target of rapamycin complex 2 (mTORC2)-dependent AKT phosphorylation, cell proliferation and cytokine secretion, including that of IL2 and TNF (PubMed:32647003)

The "NCKAP1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCKAP1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets